Aflibercept is a fusion protein and is not metabolized by CYP enzymes. No potential porphyrinogenic effects are expected.

Aflibercept is a recombinant fusion protein.

Aflibercept is indicated for the treatment of neovascular (wet) age-related macular degeneration. Visual impairment due to macular degeneration secondary to retinal vein occlusion, diabetic macular oedema or due to myopic choroidal neovascularization. Aflibercept is administered by intravitreal injections.

A small amount of the drug enters the systemic circulation (Avary 2014).

Free aflibercept binds to vascular endothelial growth factor to form a stable, inert complex. As with other large proteins, both free and bound aflibercept are expected to be cleared by proteolytic catabolism (SPC). The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept (drugbank).